It’s one of the most well-documented problems in clinical research, yet year after year, it persists: the vast majority of clinical trials fail to enroll on time. But the reason this keeps happening is not because “enrollment is simply too slow.”
Think of it this way. The average recreational marathoner finishes in about four and a half hours. If a running coach promised every athlete a three-hour finish, then reported each one as "an hour and a half behind pace," we wouldn't blame the runners—we'd question the forecast.
This leaves us with daunting stats around missed targets and doubled enrollment timelines. So why does this keep happening? And what are the sponsors who do enroll on time doing differently?
The Forecasting Problem No One Wants to Talk About
Most enrollment forecasting still relies on the same approach it did a decade ago: a combination of historical averages, unrealistic assumptions, and spreadsheets utilizing algebra.
Here’s the issue. A study might plan for 50 sites across 12 countries, and using this approach assumes every site is enrolling at a consistent rate. But the reality is far messier. Country-level regulatory approvals vary wildly—some take weeks or even months. Site activation distribution timelines are varied or getting longer, not shorter, with budget negotiations and contract finalization remaining the top barriers. And once sites are open, roughly half will meet or exceed their enrollment targets while the other half will under-enroll or enroll no one at all. Throw in the impact of screen failures that have been underestimated, or not estimated at all, and very quickly we end up with unrealistic and unreliable forecasts.
When your forecast doesn’t account for this variability, you’re not planning—you’re hoping.
This problem is only getting harder, not easier. Protocol complexity has exploded over the past two decades. Endpoints per protocol and procedures per protocol have increased dramatically. Trials now span significantly more countries than they did 20 years ago. Each layer of complexity makes accurate forecasting more difficult—and more critical.
The sponsors who consistently hit enrollment timelines share a few common traits. They don’t necessarily have better sites or simpler protocols. What they do have is a fundamentally different approach to forecasting and operational decision-making.
The financial cost of enrollment delays is well-documented. But there’s a less-discussed cost: organizational credibility. When a clinical operations team repeatedly misses enrollment timelines, it erodes trust with executive leadership, with the sites who committed resources based on the sponsor’s projections, and with the patients who need these therapies.
Moving From Reactive to Predictive
The technology to solve this problem exists today. AI-powered benchmarking can match your protocol against comparable studies and generate realistic country-level enrollment rates. Simulation modeling can quantify the range of possible outcomes rather than producing a single unreliable number. A sophisticated forecasting engine is built to ingest the inputs that matter to deliver forecasts that have the high chance of succeeding. And integrated planning platforms can connect your forecast to your actual site activation and enrollment data so that the plan stays current as reality unfolds.
The question is no longer whether better forecasting is possible. It’s whether your organization is willing to move beyond the spreadsheet.
ProofPilot’s Enrollment Forecaster uses Bayesian simulation modeling and AI-powered benchmarking across 400,000+ trials and 60+ countries to help sponsors replace guesswork with confidence.